The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China

Wang, Yan1,2,3; Shen, Guizhou4; Lu, Ruichao5; Liu, Jun6; Zhang, Feng7; Wang, Hui8; Cai, Weiping9; Zhang, Fujie3,10

2024-03-01

10.1016/j.ijid.2023.12.014

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES   影响因子和分区

1201-9712

1878-3511

Background: Existing research has provided evidence of changes in hepatitis delta virus (HDV) prevalence worldwide. This study aimed to investigate the prevalence and molecular characteristics of HDV to elucidate its spread in China. Methods: A total of 3,000 samples were collected from 2,241 HBV monoinfections and 759 HBV/HIV-1 coinfections across 13 sites in northern, southern, western, and southwestern China. Serological and virological prevalence were determined by detecting anti-HDV antibodies and HDV RNA. Results: The study revealed a 2.63% (95% CI: 2.06-3.21) seroprevalence of HDV among HBV infections in China, exhibiting regional variation. HDV seroprevalence was notably higher at 7.91% (95% CI: 5.98-9.83) in HBV and HIV-1 coinfections. Region and HIV-1 infection were identified as risk factors for HDV infection. Virological prevalence was 0.67% (95% CI: 0.38-0.96) in HBV infections and 2.24% (95% CI: 1.18-3.29) in HBV/HIV-1 coinfections. The predominant HDV genotype in China was HDV-2a, followed by HDV-1. Participants with anti-HDV positivity demonstrated significantly higher proportions of abnormal liver dysfunction and elevated HBV DNA load (P < 0.001) compared to anti-HDV-negative participants. Conclusions: This study highlights the HDV epidemic in China, sheds light on its geographical distribution and high-risk populations, and provides insights for developing strategies to manage the spread of HDV in the country. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY -NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

HDV HBV HIV-1 Epidemiology

SCI

英语

其他

John C. Martin Foundation[2017-G14]

Infectious Diseases

Infectious Diseases

WOS:001176042000001

ELSEVIER SCI LTD

IMMUNOLOGY

Web of Science

1.Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
2.Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
3.Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China
4.First Peoples Hosp Liangshan Yi Autonomous Prefec, Ganluo, Sichuan, Peoples R China
5.Chest Hosp Guangxi Zhuang Autonomous Reg, Liuzhou, Guangxi, Peoples R China
6.Third Peoples Hosp Kunming, Dept HIV AIDS, Kunming, Yunnan, Peoples R China
7.Hlth Commiss, Xinjiang, Peoples R China
8.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
9.Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Guangdong, Peoples R China
10.Capital Med Univ, Beijing Ditan Hosp, Dept Obstet & Gynecol, 8 Jingshun Dongjie, Beijing 100015, Peoples R China

Wang, Yan,Shen, Guizhou,Lu, Ruichao,et al. The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,2024,140.

Wang, Yan.,Shen, Guizhou.,Lu, Ruichao.,Liu, Jun.,Zhang, Feng.,...&Zhang, Fujie.(2024).The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China.INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,140.

Wang, Yan,et al."The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China".INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 140(2024).